<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7346995\results\search\testTrace\results.xml">
  <result pre="the original work is properly cited. Abstract Although a viral" exact="infection" post="is a major triggering factor of asthma and allergic"/>
  <result pre="targeting type 2 inflammation) and allergen immunotherapy should continue the" exact="treatment" post="while minimizing hospital and face-to-face visits. It is essential"/>
  <result pre="In addition, an important issue is the spreading of this" exact="infection" post="to healthcare workers (HCWs). In China, 3.8% of the"/>
  <result pre="63% of the affected HCWs were reported in Wuhan.4 The" exact="prevalence" post="of allergic diseases, including asthma and allergic rhinitis (AR),"/>
  <result pre="in Korea have restricted entrance to the hospital through strict" exact="screening" post="of people by checking recent travel history, clinical symptoms"/>
  <result pre="PATIENTS WITH ASTHMA AND ALLERGIC DISEASES Although a respiratory viral" exact="infection" post="is a major contributing factor to asthma exacerbation as"/>
  <result pre="remain unclear. Another report from Wuhan observed a markedly lower" exact="prevalence" post="of asthma (5 asthmatics among 548 patients with confirmed"/>
  <result pre="among 548 patients with confirmed COVID-19, 0.9%) compared to the" exact="prevalence" post="of adult asthma in Wuhan (6.4%).12 In another recent"/>
  <result pre="anti-immunoglobulin E (IgE), anti-interleukin (IL)-5 and anti-IL-4 antibodies, has improved" exact="treatment" post="outcomes with reduction in medications including systemic corticosteroids. As"/>
  <result pre="HCWs and patients (&amp;gt;3 years). During the COVID-19 pandemic, home" exact="isolation" post="strategy is necessary to control this highly contagious disease,"/>
  <result pre="of exposure to the virus. To prevent the risk of" exact="infection" post="and to provide safe medical services, the following control"/>
  <result pre="visit the hospital, they should be asked to take strict" exact="screening" post="of COVID-19 at the entrance and exit. Only patients"/>
  <result pre="Any confirmed cases of COVID-19 should stop AIT until this" exact="infection" post="completely resolves and the viral test result becomes negative.23"/>
  <result pre="suggested that asthma does not increase the risk of COVID-19" exact="infection" post="or related complications.31113 However, these data have been obtained"/>
  <result pre="strictly monitored. Additionally, it is recommended that regular Ig replacement" exact="treatment" post="be maintained in asthmatic patients with IgG subclass deficiency"/>
  <result pre="from frequent asthma exacerbations.30 Such patients should receive IgG replacement" exact="treatment" post="during the pandemic, even though they have the risk"/>
  <result pre="control status, the clinical necessity and potential risk of droplet" exact="infection" post="are compared carefully based on the judgment of the"/>
  <result pre="perform spirometry only when its results can draw an immediate" exact="treatment" post="descision.33 No specific documents are available for the management"/>
  <result pre="the management of AR during the COVID-19 pandemic; therefore, stepwise" exact="treatment" post="should be performed according to symptom severity. However, given"/>
  <result pre="data from the American CDC, it is found that the" exact="prevalence" post="of asthma in children (n = 345) with COVID-19"/>
  <result pre="taking these medications or to avoid oral steroids for the" exact="treatment" post="of an acute asthma attack even if it is"/>
  <result pre="the current pandemic, asthmatic children should continue to receive preventive" exact="treatment" post="in order to be under good control. There have"/>
  <result pre="and topical immunosuppressive agents would be preferable options in the" exact="treatment" post="of AD. However, systemic immunosuppressant or immune-modulating agents, such"/>
  <result pre="symptoms. Patients are required to follow all the policies for" exact="infection" post="control. Physicians should delay the evaluation of the causes"/>
  <result pre="needs to be performed in the hospital according to the" exact="infection" post="control procedure.44 BIOLOGIC TREATMENT Regular administration of biologics, such"/>
  <result pre="as anti-IL-5, anti-IL-4 and anti-IgE antibodies, has become a common" exact="treatment" post="option for severe asthma as well as for uncontrolled"/>
  <result pre="visit an allergy clinic to receive medications according to a" exact="treatment" post="protocol. In these patients, it is advisable to provide"/>
  <result pre="have been no systematic studies on this.46 When children under" exact="treatment" post="with biologics are infected with COVID-19 and present with"/>
  <result pre="infected with COVID-19 and present with only mild symptoms, the" exact="treatment" post="can be continued. However, when either adults or children"/>
  <result pre="either adults or children who develop severe COVID-19 symptoms, the" exact="treatment" post="should be delayed until they completely recover. CONCLUSION It"/>
  <result pre="of aggravating asthma or allergic diseases. Detailed monitoring and optimal" exact="treatment" post="with AIT, ICS and biologics need to be continued"/>
  <result pre="the Chinese Center for Disease Control and PreventionJAMA202032312391242 5ParkSYKimJHKimHJSeoBKwonOYChangHSet al.High" exact="prevalence" post="of asthma in elderly women: findings from a Korean"/>
  <result pre="health database and adult asthma cohortAllergy Asthma Immunol Res20181038739629949835 6ZhangYZhangLIncreasing" exact="prevalence" post="of allergic rhinitis in ChinaAllergy Asthma Immunol Res20191115616930661309 7XuSLiYBeware"/>
  <result pre="2019 in ChinaN Engl J Med20203821708172032109013 14ZhengXYXuYJGuanWJLinLFRegional, age and respiratory-secretion-specific" exact="prevalence" post="of respiratory viruses associated with asthma exacerbation: a literature"/>
  <result pre="reviewAllergy20116645846821087215 18ChaudharyNSDonnellyJPMooreJXBaddleyJWSaffordMMWangHEAssociation of baseline steroid use with long-term rates of" exact="infection" post="and sepsis in the REGARDS cohortCrit Care20172118528701217 19RhyouHINamYHEfficacy of"/>
  <result pre="ChinaJAMA202032310611069 26collab: World Health OrganizationClinical management of severe acute respiratory" exact="infection" post="(SARI) when COVID-19 disease is suspected [Internet]GenevaWHO2020cited 2020 May"/>
  <result pre="for asthma: a case-control studyJ Allergy Clin Immunol200411341541915007339 35LuXZhangLDuHZhangJLiYYQuJet al.SARS-CoV-2" exact="infection" post="in childrenN Engl J Med20203821663166532187458 36collab: CDC COVID-19 Response"/>
  <result pre="Dermatol Venereol2020341074107931733162 40FerrucciSRomagnuoloMAngileriLBertiETavecchioSSafety of dupilumab in severe atopic dermatitis and" exact="infection" post="of COVID-19: two case reportsJ Eur Acad Dermatol VenereolForthcoming2020"/>
  <result pre="COVID-19: two case reportsJ Eur Acad Dermatol VenereolForthcoming2020 41BernsteinJALangDMKhanDACraigTDreyfusDHsiehFet al.The" exact="diagnosis" post="and management of acute and chronic urticaria: 2014 updateJ"/>
 </snippets>
</snippetsTree>
